- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 1.5MB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 1.2MB)
Apalutamide – July 2022
Apalutamide: Tablet 60 mg; Erlyand®
Last updated
28 October 2022